Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituxan for prevention of acute GVHD after unrelated donor HCT
NCT01044745Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Dec 2009
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in graft-versus-host disease (GVHD), sponsored by University of Nebraska. Started Dec 2009; status: terminated.
02
Drugs
rituximab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01044745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01044745.